Eli Lilly's Phase 3B Study Shows Modified Donanemab Titration Reduces ARIA-E Incidence In Early Alzheimer's Patients To 14% From 24%; Comparable Safety Profiles Across Groups; Largest Reduction Observed In APOE4 Gene Carriers; Results To Be Submitted For Potential Label Update
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's Phase 3B study reveals that a modified titration of Donanemab reduces ARIA-E incidence in early Alzheimer's patients from 24% to 14%. The largest reduction is seen in APOE4 gene carriers. Results will be submitted for a potential label update.
October 29, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Phase 3B study on Donanemab shows a significant reduction in ARIA-E incidence, particularly in APOE4 gene carriers. The results will be submitted for a potential label update, which could enhance the drug's marketability.
The study's positive results, especially the reduction in ARIA-E incidence, could lead to a label update, enhancing Donanemab's marketability and potentially increasing Eli Lilly's stock value. The focus on APOE4 carriers, a significant patient group, adds to the drug's appeal.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90